Browse the latest research summaries in the field of oncology for spinal cord injury patients and caregivers.
Showing 11-20 of 200 results
J Neurosurg Case Lessons, 2025 • March 10, 2025
This case report presents a 17-year-old female with spinal osteosarcoma who achieved 20-year disease-free survival following neoadjuvant chemotherapy and en bloc resection, including spinal cord amput...
KEY FINDING: En bloc resection with tumor-free margins, including the spinal cord, can lead to long-term disease-free survival in spinal osteosarcoma, challenging the notion that spinal OS has a universally poor prognosis.
International Journal of Particle Therapy, 2025 • January 1, 2025
This study compares proton SBRT to photon SBRT for spinal metastases, using variable RBE dose models to assess the impact on target coverage and sparing of organs at risk. The results suggest that IMP...
KEY FINDING: Proton therapy (IMPT) significantly improved planning target volume coverage compared to photon therapy (PH-SBRT) at both 30 Gy and 45 Gy doses.
Cancer Medicine, 2024 • January 1, 2024
This retrospective study investigated the incidence and risk factors of skeletal-related events (SREs) in 146 patients with Ewing sarcoma (EWS) treated at a single institution between 2005 and 2019. T...
KEY FINDING: SREs occurred in 23 patients during the study period, with radiation to the bone and malignant spinal cord compression being the most frequent initial events.
Cancer Immunology, Immunotherapy, 2022 • January 27, 2022
This study used single-cell RNA sequencing to map the transcriptomic landscape of chordomas, revealing significant intratumoral heterogeneity and potential therapeutic targets. The analysis identified...
KEY FINDING: Chordoma tumors exhibit significant intratumoral heterogeneity, with distinct subpopulations of chordoma cells, fibroblasts, and immune cells.
Bioactive Materials, 2022 • February 28, 2022
This study aimed to investigate the molecular mechanisms underlying the observed cell-specific effects of bioactive glasses (BGs) on giant cell tumor of bone-derived stromal cells (GCTSC) and bone mar...
KEY FINDING: BG treatment leads to a significant decrease of cell viability in tumor cells but not in bone marrow cells.
Global Spine Journal, 2023 • January 1, 2023
This systematic review and meta-analysis aimed to compare the overall survival (OS) and neurologic outcomes of complete versus incomplete surgical resection for patients with intramedullary astrocytom...
KEY FINDING: Complete resection (CR) significantly improved overall survival (OS) compared to incomplete resection (IR).
The Journal of Spinal Cord Medicine, 2023 • May 1, 2023
This case report describes a 65-year-old female who initially presented with longitudinally extensive transverse myelitis (LETM) and subsequently developed primary central nervous system lymphoma (PCN...
KEY FINDING: The patient presented with LETM and responded well to immunotherapy, but was later diagnosed with PCNSL.
CNS Oncology, 2022 • June 13, 2022
This case report highlights the rare occurrence of extranodal Hodgkin lymphoma involving the spinal cord, emphasizing the importance of considering this possibility in patients presenting with spinal ...
KEY FINDING: The study presents two cases of extranodal Hodgkin lymphoma involving the spinal cord without contiguous bone involvement, a rare presentation of the disease.
Internal Medicine, 2023 • January 1, 2023
This case report details a 14-year-old boy presenting with spinal cord compression as the initial manifestation of acute myeloid leukemia (AML). The compression was caused by an epidural mass, which w...
KEY FINDING: A rare presentation of AML in a 14-year-old boy was spinal cord compression due to an epidural mass.
Molecular Therapy: Oncolytics, 2022 • September 1, 2022
This study investigated the effect of Cln, a b2-adrenergic receptor agonist, on the bystander effect of HSV-TK/GCV gene therapy in human GBM cells using OECs as vectors. The researchers found that Cln...
KEY FINDING: Cln upregulated Cx43 expression in human GBM cells and OECs.